Lenalidomide Grindeks

Lenalidomide, the active ingredient in Lenalidomide Grindeks, is an immunomodulatory imide drug (IMiD) presented as an oral tablet for oral use. It treats multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomide Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Lenalidomide is used in hematologic malignancies and related disorders, acting on abnormal plasma cells and dysplastic bone‑marrow clones. - Multiple Myeloma: improves progression‑free survival and overall response in adult patients. - Myelodysplastic Syndromes: reduces transfusion dependence and improves blood counts in patients with del(5q) cytogenetic abnormality. - Mantle Cell Lymphoma: contributes to disease control when used in combination therapy for adult patients.

Lenalidomide may cause a range of adverse reactions, from mild to severe. Monitoring and supportive care are essential during therapy.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: low platelet count leading to easy bruising. - Diarrhea: loose stools that may require hydration. - Constipation: difficulty passing stool. - Rash: mild skin irritation or erythema.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia: profound immune suppression. - Serious infections: opportunistic or bacterial infections. - Secondary malignancies: emergence of new cancers. - Liver toxicity: elevated transaminases or hepatic failure.

Before initiating Lenalidomide, clinicians should assess patient-specific risk factors and implement appropriate monitoring. - Pregnancy: contraindicated; teratogenic risk requires effective contraception. - Thrombosis risk: evaluate history and consider prophylactic anticoagulation. - Hematologic monitoring: perform regular complete blood counts. - Renal impairment: adjust dose based on renal function. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep in original container, protect from moisture and light.

Lenalidomide interacts with several drug classes; awareness helps prevent reduced efficacy or heightened toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly lower lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Live vaccines: heightened risk of infection due to immunosuppression. - Immunosuppressants (e.g., cyclosporine): may amplify hematologic toxicity.

Moderate Interactions (Monitor Closely): - Antibiotics such as fluoroquinolones: may exacerbate myelosuppression. - Antifungals like ketoconazole: can raise plasma concentrations. - NSAIDs: potential additive renal stress. - Vaccines (non‑live): may have reduced efficacy, monitor immune response.